FDA rejects EpiCept's marketing application for cancer drug Ceplene

08/23/2010 | Wall Street Journal, The

The FDA denied EpiCept's application to market Ceplene, a drug candidate for acute myeloid leukemia, because of concerns about the treatment's effectiveness. The agency recommended an additional clinical study to verify Ceplene's efficacy when used in combination with anti-cancer agent interleukin-2.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA